Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: Open-label, randomized study
Critical Care Medicine,  Clinical Article

Makris D et al. – This study provides evidence that pravastatin may favorably affect the outcome of critical care patients.

Methods
  • Consecutive patients were recruited from the intensive care units of the two hospitals.
  • Patient inclusion criteria included mechanical ventilation and intensive care unit stay of >48 hrs.
  • The two arms consisted of treatment plus oral pravastatin sodium (40 mg) (n=71 patients, pravastatin group) and treatment without pravastatin (n=81 patients, control group).
  • Treatment was started after randomization and ended 30 days later.

Results
  • Ventilator-associated pneumonia frequency and intensive care unit mortality at 30 days and at the end of intensive care unit stay were measured.
  • Adverse events related to statin treatment in the intensive care unit were documented.
  • Sixteen patients (22.5%) in the pravastatin group and 28 (34.5%) in the control group (p=.11) presented pneumonia during the 30-day treatment period in the intensive care unit.
  • There was an indication for increased probability of being free from ventilator-associated pneumonia during the 30-day treatment period in the pravastatin group compared to the control group (p=.06) and significantly increased probability during the whole intensive care unit period of stay (p=.04) in the pravastatin group compared to the control group in the subgroup of patients with Acute Physiology and Chronic Health Evaluation scores of ≥15.
  • Six patients (8.45%) in the pravastatin group and 16 (19.85%) in the control group died during the 30-day treatment period (p=.06), whereas 10 (14.1%) patients in the pravastatin group and 24 (29.1%) patients in the control group died during the whole period of intensive care unit stay (p=.03).
  • Pravastatin group patients with Acute Physiology and Chronic Health Evaluation scores of ≥15 had significantly increased probability of survival compared to controls during the 30-day treatment period (p=.04).
  • Creatine kinase and hepatic function enzyme levels during the whole study period were not significantly different between the pravastatin group and control group.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pulmonology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pulmonology Articles

1 Cytotoxic agents in sarcoidosis: Which one should we choose? Current Opinion in Pulmonary Medicine, August 15, 2014    Review Article

2 Is non-invasive ventilation safe in acute severe asthma? Respirology, November 11, 2014    Review Article

3 Maternal vitamin D and E intakes during pregnancy are associated with asthma in children European Respiratory Journal , November 6, 2014    Clinical Article

4 Study shows possible link between asthma, cardiovascular disease University of Wisconsin-Madison News, November 20, 2014

5 Multicentric study on the beta-blocker use and relation with exacerbations in COPD Respiratory Medicine, June 19, 2014    Clinical Article

6 Efficacy of azithromycin in the treatment of bronchiectasis Respirology, September 9, 2014    Clinical Article

7 Efficacy of mycophenolate mofetil in sarcoidosis Respiratory Medicine, October 29, 2014    Review Article

8 Efficacy and safety of a fixed-dose combination of indacaterol and glycopyrronium for the treatment of COPD: A systematic review Chest, August 21, 2014    Evidence Based Medicine

9 Application of a new parameter in the 6-minute walk test for manifold analysis of exercise capacity in patients with COPD Full Text International Journal of COPD, November 24, 2014    Free full text    Clinical Article

10 Prophylactic antibiotic therapy after inhalation injury Burns, October 10, 2014    Clinical Article

11 Withdrawal of inhaled glucocorticoids and exacerbations of COPD New England Journal of Medicine, September 12, 2014    Evidence Based Medicine    Clinical Article

12 Microfibrillar-associated protein 4: A potential biomarker of chronic obstructive pulmonary disease Respiratory Medicine, September 19, 2014    Clinical Article

13 Prevalence of chronic obstructive pulmonary disease among US working adults aged 40 to 70 years: National Health Interview Survey data 2004 to 2011 Journal of Occupational and Environmental Medicine, October 17, 2014    Clinical Article

14 Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): A randomised, double-blind, placebo-controlled trial The Lancet Respiratory Medicine, May 15, 2014    Clinical Article

15 A cytomorphometric analysis of pulmonary and mediastinal granulomas: Differentiating histoplasmosis from sarcoidosis by fine-needle aspiration Cancer Cytopathology, November 5, 2014    Review Article

16 Clinical phenotypes in sarcoidosis Current Opinion in Pulmonary Medicine, August 12, 2014    Review Article

17 Noninvasive ventilation with complex critical care ventilator in the treatment of acute exacerbation of chronic obstructive pulmonary disease The Journal of International Medical Research, August 12, 2014    Clinical Article

18 Endobronchial ultrasound-guided transbronchial biopsy and brushing: A comparative evaluation for the diagnosis of peripheral pulmonary lesions European Journal of Cardio-Thoracic Surgery, April 18, 2014    Review Article

19 Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen Respiratory Medicine, February 3, 2014    Clinical Article

20 Long-term outcomes after in-hospital CPR in older adults with chronic illness Chest, November 14, 2014    Clinical Article

Indexed Journals in Pulmonology: Chest, Thorax, American Journal of Respiratory and Critical Care Medicinemore